Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Wegovy is already approved to treat obesity in children ages 12 and older, but there are currently no approved medications for those under 12.
Wegovy is already approved to treat obesity in children ages 12 and older, but there are currently no approved medications for those under 12. This story matters for Finance & Markets readers tracking fund. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. FundNews.com curates and briefs the finance & markets stories that matter. Our editorial policy →
Get the daily fund signal